Please assess the completion status of the following clinical trial:

Trial Title: The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent;~* Male or postmenopausal female;~* Age ≥45 and ≤59 years old;~* The body mass index (BMI) ≥18.5kg/m2 and ≤28 kg/m2;~* T value of areal bone mineral density on any lumbar spine (L1-L4) or collum femoris\>-2.5 and \<-1;~* The comprehensive physical examination is eligible or slightly abnormal but the researchers determine no clinical implication;~* No smoking, alcohol or drugs abuse.~Exclusion Criteria:~* Any disease affecting bone metabolism;~* Past medical history of cerebral infarction or cerebral arterial thrombosis;~* Past medical history of myocardial infarction;~* Administration of the following drugs within 6m: Hormone replacement therapy, Calcitonin Parathyroid hormone (or any derivative), Supplemental Vitamin D\>1,000 IU/day, Glucocorticosteroids (inhaled or topical corticosteroids administered more than 2 weeks before the enrollment date are allowed), Anabolic steroids, Calcitriol and available analogues, thiazide diuretics;~* Administration of the following drugs within 12m: Bisphosphonates, Fluoride for osteoporosis;~* A bone fracture within the previous 6 months;~* A lumbar spine L1-L4 or femoral neck T-score ≤-2.5;~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic acyl transferase (GGT) or total bilirubin, more than 1.5 x ULN during screening;~* 3 months prior to screening involved in any drug clinical subjects;~* Subjects determined by the researchers have any food, dietary supplement or drugs that affect SHR-1222 absorption, distribution, metabolism and excretion in 4 weeks prior to screening or within 5 half-lives;~* Serious infection, trauma or major surgery in 4 weeks prior to screening;~* A surgery plan during the study;~* Blood donation and transfusion in 3 months prior to screening;~* Unstable thyroid dysfunction in 6 months prior to screening;~* Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive;~* Intolerant to venous blood collection;~* A clinical history of drug allergy or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known allergy to experimental or similar~* Subjects with any other situation should not be involved, which determined by the researchers.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): A single subcutaneous injection of SHR-1222 dose 1 versus placebo
- Cohort 2 (Type: EXPERIMENTAL): A single subcutaneous injection of SHR-1222 dose 2 versus placebo
- Cohort 3 (Type: EXPERIMENTAL): A single subcutaneous injection of SHR-1222 dose 3 versus placebo
- Cohort 4 (Type: EXPERIMENTAL): A single subcutaneous injection of SHR-1222 dose 4 versus placebo
- Cohort 5 (Type: EXPERIMENTAL): A single subcutaneous injection of SHR-1222 dose 5 versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete